LOGIN  |  REGISTER
Astria Therapeutics

Cryo-Cell (NYSEAMEX: CCEL) Stock Quote

Last Trade: US$8.90 -0.10 -1.11
Volume: 11,196
5-Day Change: 3.85%
YTD Change: 54.78%
Market Cap: US$72.090M

Latest News From Cryo-Cell

OLDSMAR, Fla. / Apr 15, 2024 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024. Financial Results Revenue The revenues for the first quarter of fiscal 2024 were $7.85 million compared to $7.82 million for the first quarter of... Read More
OLDSMAR, Fla. / Mar 25, 2024 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post... Read More
OLDSMAR, Fla. / Feb 28, 2024 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023. Financial Results Revenue Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022. The revenues for fiscal 2023... Read More
OLDSMAR, Fla. / Oct 12, 2023 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third... Read More
OLDSMAR, Fla. / Jul 14, 2023 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2023 were $7.77 million compared to $7.63 million for the second quarter of... Read More
OLDSMAR, Fla. / Apr 21, 2023 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023. Financial Results Revenue The revenues for the first quarter of fiscal 2023 were $7.82 million compared to $7.26 million for the first quarter of... Read More
OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021. The revenues for fiscal 2022... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB